NCT02755675

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Rigshospitalet, Denmark · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

uPAR PET/CT as a prognostic marker in non-small cell lung cancer.

Detailed description

Study I: uPAR PET/CT with 68Ga-NOTA-AE105 will be evaluated as a prognostic tool in patients with non-small cell lung cancer (NSCLC) (stage IV (Ia) operable disease (Ib)) by observer-blinded readings and compared to the prognostic performance of FDG PET/CT and prognostic biomarkers as uPAR. Furthermore, uPAR PET/CT will be evaluated in a pilot study in patients with malignant pleural mesothelioma (MPM) (Study II) and large cell neuroendocrine carcinoma of the lung (LCNEC) (Study III) and correlated with immunohistochemical uPAR expression.

Conditions

• Non-small Cell Lung Cancer
• Malignant Pleural Mesothelioma
• Large Cell Neuroendocrine Carcinoma of the Lung

Interventions

Type	Name	Description
OTHER	68Ga-NOTA-AE105 PET/CT	Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT

Timeline

• Start date: 2016-04-01
• Primary completion: 2023-04-01
• Completion: 2023-10-01
• First posted: 2016-04-29
• Last updated: 2016-11-21

Locations

1 site across 1 country: Denmark